Targeting IAP proteins in combination with radiotherapy.
The efficacy of radiotherapy critically depends on the activation of intrinsic cell death programs in cancer cells. This implies that evasion of cell death, a hallmark of human cancers, can contribute to radioresistance. Therefore, novel strategies to reactivate cell death programs in cancer cells are required in order to overcome resistance to radiotherapy. Since Inhibitor of Apoptosis (IAP) proteins are expressed at high levels in multiple cancers and block cell death induction at a central point, therapeutic targeting of IAP proteins represents a promising approach to potentiate the efficacy of radiotherapy. The current review discusses the concept of targeting IAP proteins in combination with radiotherapy.
Institute for Experimental Cancer Research in Pediatrics, Goethe-University, Komturstr. 3a, 60528, Frankfurt, Germany. simone.fulda@kgu.de.|German Cancer Consortium (DKTK), Heidelberg, Germany. simone.fulda@kgu.de.|German Cancer Research Center (DKFZ), Heidelberg, Germany. simone.fulda@kgu.de.
Simone
S
Fulda
D017209:Apoptosis / Q000528:radiation effects*; D003131:Combined Modality Therapy; D006801:Humans; D051034:Inhibitor of Apoptosis Proteins / Q000037:antagonists & inhibitors*; D058990:Molecular Targeted Therapy; D009369:Neoplasms / Q000378:metabolism* / Q000473:pathology / Q000532:radiotherapy*; D011379:Prognosis; D011838:Radiation-Sensitizing Agents / Q000627:therapeutic use*; D011878:Radiotherapy; D015398:Signal Transduction / Q000528:radiation effects
D051034:Inhibitor of Apoptosis Proteins; D011838:Radiation-Sensitizing Agents